Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity. [PDF]
Cardiovasc ToxicolSzubińska-Bałaban P +9 more
europepmc +1 more source
An oncologic cardiotoxicity masquerading as ST-elevated myocardial infarction: a case report. [PDF]
Eur Heart J Case RepSingh AK, Rafiudeen R, Wong C.
europepmc +1 more source
Oxaliplatin versus irinotecan as first-line therapy in metastatic colorectal cancer with prior adjuvant treatment: a retrospective study on efficacy, sequential therapy, and the impact of thrombocytopenia. [PDF]
Front OncolShan H, Huang S, Zhou C, Wang M, Du Q.
europepmc +1 more source
Retrospective study on maintenance therapy with PD-1 inhibitor combined with S-1 or capecitabine after first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. [PDF]
Am J Cancer ResYuan H, Wang Y, Tan J, Lin X, Wei Y.
europepmc +1 more source
Bridging mechanism and design: modern medicinal chemistry approaches to thymidylate synthase inhibitors. [PDF]
RSC AdvAl-Karmalawy AA +4 more
europepmc +1 more source
Capecitabine-Induced Hand-Foot Syndrome With Genital Involvement. [PDF]
J Adv Pract OncolFeng Y, Baroody C, Al Mutar S.
europepmc +1 more source
Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial. [PDF]
ESMO Gastrointest OncolTintelnot J +11 more
europepmc +1 more source
Case Report: Cardiotoxicity of capecitabine may manifest as STEMI with significant left ventricular cardiac dysfunction and recurrent supraventricular and ventricular arrhythmias: a proposal for optimal diagnosis and treatment. [PDF]
Front OncolSzmit S +6 more
europepmc +1 more source